Joint benchmarks on OCI H100 infrastructure showed 10x more concurrent users, 10x higher token throughput, and 7x more tokens served without adding GPUs

CAMPBELL, Calif., June 10, 2026 /PRNewswire/ — WEKA, the AI data and memory infrastructure company, today announced production-scale benchmarks that show how organizations can improve the economics of long-context AI inference by serving more users and tokens on the same GPU footprint. The benchmarks show that WEKA’s NeuralMesh™ platform with Augmented Memory Grid™ on Oracle Cloud Infrastructure (OCI) serves 10x more concurrent users, delivers 10x higher token throughput, and produces 7x more tokens per GPU than DRAM-only configurations without adding infrastructure. The results were validated on a nine-node OCI bare-metal H100 cluster with 100,000-token context windows.

“Enterprise AI workloads are pushing context windows and GPU utilization to new limits,” said Pablo Selem, senior director, software development, Oracle Cloud Infrastructure. “These benchmarks show how WEKA’s NeuralMesh platform with Augmented Memory Grid on OCI helps remove memory bottlenecks so customers can support larger, more demanding inference workloads without simply adding more GPUs.”

Three Outcomes That Change the Math on Inference
Validated at production scale on a bare-metal H100 cluster (nine nodes, 72 GPUs, 100,000-token context windows, thousands of concurrent users), NeuralMesh with Augmented Memory Grid on OCI delivered:

• 10x more concurrent users served, without adding infrastructure. NeuralMesh with Augmented Memory Grid scaled past 5,000 concurrent users vs. about 600 for DRAM-only configurations. This eliminates the failure cliff that hits when cache saturates by expanding the active cache working set from 8.64 TiB of DRAM to 287 TiB of usable NVMe. In addition, more users per GPU means the same investment stretches further.
• 10x higher token throughput. More output from every GPU in the cluster. On OCI, NeuralMesh with Augmented Memory Grid reached approx. two million tokens per second, compared to under 200,000 for the DRAM-only baseline. For product teams running real-time AI features, including search, summarization, code assist, and multi-turn agents, the throughput determines the ceiling for how many users can be served, how fast features respond, and how much revenue the infrastructure can support.
• 7x more tokens served. Lower cost per token at scale. NeuralMesh with Augmented Memory Grid served five billion tokens, compared to 700 million for the DRAM-only baseline, in a single one-hour, 2,400-user test. For organizations running agentic workflows, DRAM saturation quietly drains GPU capacity through constant recomputation, creating a direct hit on cost per token and ROI.

“Inference is bottlenecked by how much effective memory is available to GPUs,” said Liran Zvibel, CEO of WEKA. “These results prove that AI token economics aren’t solved by hardware alone; they’re solved by eliminating the memory wall that has been the real ceiling on what existing hardware can do. NeuralMesh with Augmented Memory Grid running on OCI brings orders of magnitude more tokens to customers in an extremely cost-efficient way.”

Transforming AI Economics with Context Memory Infrastructure
As inference demand grows, AI infrastructure inefficiencies compound. Every key-value (KV) cache eviction is a tax: on GPU cycles, latency, user experience, and the cost of every token served. For long-context and agentic workloads, where inputs routinely run to 100,000 tokens or more, that tax is not a rounding error. It is a direct hit on the unit economics of every organization running production AI.

Augmented Memory Grid, a capability of NeuralMesh, solves the problem at the architectural level by decoupling KV cache from local GPU memory and storing it in a high-performance token warehouse accessible across the cluster. Any host can serve any session with cache hits intact, eliminating rigid session stickiness while delivering superior performance to DRAM, improving load balancing, and enabling clean horizontal scaling as concurrency grows. The result is persistent context memory for AI agents and the cost lever that makes long-context inference economical to run at scale.

Production-Grade Proof
OCI published the full benchmark methodology, system configuration, and results on its AI & Data Science blog on May 13, 2026. The benchmarks, executed on a nine-node OCI bare-metal H100 cluster, move beyond the prior phase of validation, which demonstrated 1000x more KV cache capacity and up to 20x faster time to first token at 128,000 tokens. This latest phase tests the full economics of inference in production: concurrency density, sustained throughput, cache persistence, and service level objective (SLO) stability when demand spikes under high load.

Available on Oracle Marketplace
NeuralMesh with Augmented Memory Grid is generally available to WEKA customers and on the Oracle Marketplace, with OCI as WEKA’s exclusive cloud launch partner. Organizations running long-context inference on OCI can deploy a validated, production-ready architecture today. For more on the OCI and WEKA Augmented Memory Grid benchmark, read the OCI blog: https://blogs.oracle.com/ai-and-datascience/scaling-long-context-inference-on-oci-with-wekas-augmented-memory-grid.

About WEKA
WEKA is the AI data and memory infrastructure company transforming the economics of agentic AI. Its NeuralMesh™ platform unifies high-performance data storage with extended GPU memory, giving enterprises, AI cloud providers, and AI builders a single foundation for training, inference, and agentic workloads. With Augmented Memory Grid, NeuralMesh extends GPU memory capacity by 1000x, accelerates time to first token by up to 20x, and delivers 10x more concurrent users from the same GPU footprint, proven in production benchmarks. Trusted by 30% of the Fortune 50, WEKA enables organizations to scale AI faster, optimize GPU utilization, and reduce the cost of every token served. Learn more at www.weka.io or connect with us on LinkedIn and X.

WEKA and the W logo are registered trademarks of WekaIO, Inc. Other trade names herein may be trademarks of their respective owners.

Source

• COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease
• HBM9378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026
• HBM9378/WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody for asthma and COPD, with Phase 3 initiation in asthma planned for Q4 2026

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 9, 2026 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that its partner Windward Bio has dosed the first patients in the Phase 2 SIRIUS study of HBM9378/WIN378 (also known as SKB378) in patients with chronic obstructive pulmonary disease (COPD).

COPD is a progressive, irreversible lung disease and the third leading cause of death worldwide. Driven by immune-mediated airway inflammation and persistent airflow obstruction, the disease makes even routine daily activities a struggle. Its defining feature is exacerbations — sudden, severe flare-ups that lead to emergency room visits, hospitalizations, and lasting declines in lung function. Despite currently available inhaled background therapies, more than 3 million patients with moderate-to-severe COPD remain at high risk of recurrent exacerbations, underscoring an urgent need for better treatment options.

SIRIUS is a global, Phase 2 randomized, double-blind, placebo-controlled, dose-finding study. It is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9378/WIN378 in patients with moderate-to-severe COPD.

“We are very pleased to see the continued clinical advancement of HBM9378/WIN378 by our partner Windward Bio with the initiation of the Phase 2 SIRIUS COPD study,” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. “This milestone further highlights the potential of HBM9378/WIN378 as a differentiated, ultra long-acting anti-TSLP antibody for immunological diseases. As one of the originators of this promising molecule and a new investor in Windward Bio, we strongly believe in the potential of HBM9378/WIN378 and Windward Bio’s execution capabilities. We look forward to supporting the continued advancement of the program and ultimately bringing innovative treatment options to patients living with COPD worldwide.”

About HBM9378/WIN378

HBM9378/WIN378 (also known as SKB378) is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. HBM9378/WIN378 has been engineered to achieve half-life extension (HLE) and have a silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. HBM9378/WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Harbour BioMed (also known as HBM9378) and Kelun-Biotech (also known as SKB378). HBM9378/WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. HBM9378/WIN378 is also being evaluated in the SIRIUS Phase 2 COPD study. The first Phase 3 study of HBM9378/WIN378 in asthma is expected to begin in the fourth quarter of 2026.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice^®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS^TM) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice^® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx^TM AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice^®, HBICE^®, HCAb PLUS^TM, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead program is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma and in a Phase 2 study for COPD. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions.

Source

SHANGHAI, June 9, 2026 /PRNewswire/ — As spatial computing moves further into professional, enterprise, educational, and creative workflows, DFRobot today introduced the seeMote series for Apple Vision Pro developers, including seeMote Cap and seeMote Cube. The new series is designed to help developers integrate physical tools, handheld controls, and real-world actions into visionOS applications.

The seeMote series brings physical spatial input to visionOS applications, ranging from 6DoF tracking for real-world tools to handheld controls with buttons and haptics.

seeMote Cap is a mountable spatial accessory tracking module that brings 6DoF motion detection from real-world objects into visionOS apps. seeMote Cube is a handheld spatial device with buttons and haptics, enabling developers to build more interactive and immersive visionOS apps.

As developers explore more professional and task-specific visionOS applications, physical input is becoming an important part of the experience. For applications such as training, guided repair, design review, medical and laboratory education, and spatial content creation, the next step is not only what users see in space, but how real-world actions can become part of the app experience.

seeMote is designed for this emerging layer of physical spatial input.

Introducing Physical Tools and Handheld Controls to visionOS Apps

seeMote Cap is built for real-world tools. The compact module can be mounted to objects such as pens, screwdrivers, training instruments, laboratory tools, education props, and other custom handheld objects. Once attached, it enables the object to provide 6DoF motion input, including position, orientation, and motion-state data. Developers can use this data to map real tool movement into visionOS apps while preserving the grip, feel, and operating habits of physical tools.

seeMote Cube is built for developers who need a more flexible handheld input device. With buttons and haptics, Cube gives teams a compact way to prototype spatial controls, object-based interactions, and custom workflows for visionOS apps. Where Cap brings existing tools into spatial applications, Cube gives developers a developer-friendly device for building new interaction patterns.

Together, seeMote Cap and seeMote Cube offer two complementary ways to connect physical input with Apple Vision Pro applications: attach spatial tracking to the objects people already use, or prototype new handheld controls for experiences that need more direct interaction.

Use Cases

The seeMote series can support developers working on professional, enterprise, educational, and creative visionOS applications.

Industrial training and guided repair: Track real tools such as screwdrivers, wrenches, and other training equipment as users follow spatial instructions.

Medical and laboratory education: Bring physical training tools, lab instruments, and procedural objects into interactive learning experiences.

Design review and simulation: Use handheld spatial input to inspect, annotate, or manipulate 3D content with more physical context.

Spatial content creation: Give creators new ways to control, draw, trigger, or interact with spatial scenes using real-world objects and handheld inputs.

“As developers explore more professional and task-specific visionOS applications, physical input becomes an important part of the experience,” said Ricky Ye, CEO of DFRobot. “With seeMote Cap and seeMote Cube, we are excited to support visionOS developers and give them more ways to connect real-world tools, handheld controls, and physical actions with spatial applications. We see strong potential in use cases such as industrial training, guided work, medical education, design review, and spatial content creation.”

Availability

seeMote Cap and seeMote Cube are planned to be available on DFRobot.com in Fall 2026. Developers can learn more and sign up for launch updates at https://www.dfrobot.com/seemote.

Developers can also learn more about building for visionOS through the Apple Developer website.

Source

Source: Ningbo Smooth Electric Manufacture Co., Ltd.

Source

HAWALLY, Kuwait, June 8, 2026 /PRNewswire/ — Following Bloomberg coverage on the 2nd of June, Goldman Sachs is working with Boutiqaat on preparations for a potential listing that could take place as early as the first quarter of 2027. The news offering could value the company at more than US$1 billion, positioning it among the largest private-sector listings in Kuwait’s history.

Over the years, Boutiqaat has evolved into a premier destination for discerning consumers across the Middle East, offering a comprehensive portfolio of beauty, fragrance, fashion, and lifestyle products for women, men, and children. The company’s sustained success reflects its ability to establish strategic partnerships with globally recognized brands across Europe, North America, and Asia, while consistently introducing innovative retail concepts and experiences that resonate with regional consumers. This approach has enabled Boutiqaat to build a trusted platform that delivers authenticity, quality, and exceptional customer service to a growing base of loyal customers throughout the region.

A cornerstone of Boutiqaat’s expansion strategy is Korea Town by Boutiqaat, a pioneering retail destination dedicated to Korean beauty and lifestyle products. This strategic initiative positions the company at the heart of one of the world’s fastest-growing and most influential beauty markets, creating a distinctive competitive advantage in the regional retail landscape.

Korea Town by Boutiqaat continues to unlock new opportunities for collaboration with leading Korean brands and manufacturers, strengthening Boutiqaat’s presence within the global K-beauty ecosystem. Through this platform, the company is building a powerful network for long-term growth, innovation, and cross-border business development that extends beyond traditional retail boundaries.

The success of Korea Town by Boutiqaat demonstrates the company’s ability to identify and capitalize on emerging market trends while creating unique value propositions that differentiate it from competitors. As Korean beauty and lifestyle products continue to gain popularity worldwide, Boutiqaat’s early investment in this sector positions the company to capture substantial growth opportunities in the coming years.

A public listing by Boutiqaat would represent a landmark moment for Kuwait’s private sector, demonstrating the country’s growing attractiveness to international investors and its potential as a hub for high-growth, consumer-driven businesses. The move would also highlight the maturity and sophistication of the regional retail and e-commerce sector, which has experienced significant transformation and expansion in recent years.

A successful IPO would underscore Kuwait’s position as a promising destination for innovative companies seeking access to capital markets while maintaining strong operational foundations in the region. It would also reflect the confidence of international financial institutions in the strength and potential of Kuwait’s business environment.

The company remains committed to its long-term vision of regional and international expansion while continuing to evaluate strategic opportunities that align with its growth objectives and stakeholder interests. Boutiqaat’s leadership team continues to focus on operational excellence, customer satisfaction, and sustainable growth as the company prepares for its next chapter.

Media Contact:
kt.distribution@boutiqaat.com

Source